---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031351"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:24:36.113641+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics reports Q3 net loss of $6.1M; appoints Jill Howe as CFO

## Summary
- Net loss attributable to Lineage of $6.1M ($0.04/share) vs $7.8M ($0.05/share) in Q3 2021.
- Total revenue $3.0M, up from $2.3M YoY, driven by Roche collaboration revenue.
- Cash, equivalents, and marketable securities $66.4M as of Sep 30, 2022; expected runway into Q3 2024.
- Appointed Jill Howe as CFO effective Nov 14, 2022; she has 20+ years biotech finance experience.
- Received notice of allowance for two patents covering directed differentiation methods for RPE and OPC cells.

## SEC filing metadata
- accession: 0001493152-22-031351
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315222031351/0001493152-22-031351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315222031351/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031351
- JSON: https://secwatch.observer/filing/0001493152-22-031351.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031351.txt

## Key facts
- Earnings Releases
  Lineage Cell Therapeutics, Inc. reported the third quarter of 2022 results: revenue approximately $3.0 million.
  - Period: the third quarter of 2022
  - Revenue: approximately $3.0 million
  - Result: reported results
  source text: generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended September 30, 2022 were approximately $3.0 million, a net increase of $0.7 million as compared to $2.3 million for the same period in 2021. The increase was driven by collaboration and licensing revenue recognized from deferred
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000149315222031351/0001493152-22-031351-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.